Found: 23
Select item for more details and to access through your institution.
Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 9, p. 1, doi. 10.1093/ofid/ofac448
- By:
- Publication type:
- Article
The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridiumdifficile Infection: Current Understanding and Gap Analysis.
- Published in:
- Open Forum Infectious Diseases, 2020, v. 7, n. 5, p. 1, doi. 10.1093/ofid/ofaa114
- By:
- Publication type:
- Article
Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC<sup>3</sup> Study.
- Published in:
- PLoS ONE, 2015, v. 10, n. 4, p. 1, doi. 10.1371/journal.pone.0122232
- By:
- Publication type:
- Article
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.
- Published in:
- Journal of Infectious Diseases, 2016, v. 214, n. 2, p. 173, doi. 10.1093/infdis/jiv766
- By:
- Publication type:
- Article
Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Rate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV Infection.
- Published in:
- Journal of Infectious Diseases, 2009, v. 200, n. 6, p. 877, doi. 10.1086/605444
- By:
- Publication type:
- Article
Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection—Reply.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 12, p. 1033, doi. 10.1001/jama.2023.0496
- By:
- Publication type:
- Article
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
- Published in:
- Clinical Infectious Diseases, 2021, v. 72, n. 12, p. 2132, doi. 10.1093/cid/ciaa387
- By:
- Publication type:
- Article
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
- Published in:
- Clinical Infectious Diseases, 2024, v. 78, n. 4, p. 833, doi. 10.1093/cid/ciad636
- By:
- Publication type:
- Article
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic.
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 11, p. 1504, doi. 10.1093/cid/ciad448
- By:
- Publication type:
- Article
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study.
- Published in:
- International Journal of Epidemiology, 2013, v. 42, n. 6, p. 1649
- By:
- Publication type:
- Article
Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System: A Case Series and Chart Review.
- Published in:
- 2015
- By:
- Publication type:
- Case Study
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.
- Published in:
- Journal of Infectious Diseases, 2023, v. 228, n. 10, p. 1452, doi. 10.1093/infdis/jiad298
- By:
- Publication type:
- Article
Editorial Commentary: Hepatitis C Virus and the Infectious Disease Physician: A Perfect Match.
- Published in:
- 2012
- By:
- Publication type:
- Opinion
A “One-Two Punch” Leading to Hepatitis C Seroconversion.
- Published in:
- Clinical Infectious Diseases, 2011, v. 52, n. 3, p. 361, doi. 10.1093/cid/ciq159
- By:
- Publication type:
- Article
Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria.
- Published in:
- Clinical Infectious Diseases, 2009, v. 49, n. 7, p. 1051, doi. 10.1086/605561
- By:
- Publication type:
- Article
Managing Symptomatic Drug-Induced Liver Injury in HIV—Hepatitis C Virus—Coinfected Patients: A Role for Interferon.
- Published in:
- Clinical Infectious Diseases, 2007, v. 45, n. 10, p. 1386, doi. 10.1086/522174
- By:
- Publication type:
- Article
The Impact of Cirrhosis on CD4<sup>+</sup> T Cell Counts in HIV-Seronegative Patients.
- Published in:
- Clinical Infectious Diseases, 2007, v. 44, n. 3, p. 431, doi. 10.1086/509580
- By:
- Publication type:
- Article
Hepatic Steatosis Is Associated with Fibrosis, Nucleoside Analogue Use, and Hepatitis C Virus Genotype 3 Infection in HIV-Seropositive Patients.
- Published in:
- Clinical Infectious Diseases, 2006, v. 43, n. 3, p. 365, doi. 10.1086/505495
- By:
- Publication type:
- Article
Acute Hepatitis C Virus Infection in Incarcerated Injection Drug Users.
- Published in:
- Clinical Infectious Diseases, 2006, v. 42, n. 12, p. 1663, doi. 10.1086/504327
- By:
- Publication type:
- Article